"Doctors Are Optimistic About Experimental Alzheimer's Drug"
Physicians are optimistic about the promise of experimental Alzheimer's drug RVT-101, but some are reserving judgment. "I would not say it absolutely works," says Mary Sano, PhD, Associate Dean for Clinical Research at The Mount Sinai Hospital, but moving it forward into larger studies "makes sense." Samuel Gandy, MD, also of Mount Sinai said that 5HT6 inhibitors like RVT-101 seem to have "an authentic pro-cognitive effect." They won't do more than improve symptoms temporarily but "there are plenty of patients who could benefit," Dr. Gandy said.
-Mary Sano, PhD, Professor, Psychiatry, Associate Dean for Clinical Research, Director of Alzheimer's Disease Research, Icahn School of Medicine at Mount Sinai
- Samuel Gandy, MD, Professor, Neurology, Psychiatry, Icahn School of Medicine at Mount Sinai, Director, Mount Sinai Center for Cognitive Health
Additional Coverage
WebMD